Cancer research in the United States: Dying by a thousand paper cuts

Cancer

Volumn 119, Issue 21, 2013, Pages 3742-3745

  Kantarjian, Hagop ^a   Stewart, David J ^b   Zwelling, Leonard ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CLINICAL RESEARCH; COST CONTROL; EXPERIMENTATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; PATIENT CARE; PATIENT RIGHT; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOCIOECONOMICS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONSENT FORMS; HUMAN EXPERIMENTATION; HUMANS; INTENTION TO TREAT ANALYSIS; MEDICAL ONCOLOGY; MORTALITY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84886088921     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28193     Document Type: Review

References (14)

1. US Department of Health and Human Services. The Belmont Report. hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed March 7, 2013.
2. Life Sciences World Inc. Phase 3 Clinical Trial Costs Exceed 26,000 per Patient. lifesciencesworld.com/news/view/11080. Accessed March 7, 2013.
3. Silverman E,. Pharmalot: Clinical Trials Costs Are Rising Rapidly. pharmalotcom/2011/07/clinical-trial-costs-for-each-patient-rose-rapidly/. Access date.
4. Patlak M, Nass S, Rapporteurs. Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: National Academies Press; 2008.
5. Stewart DJ, Whitney SN, Kurzrock R,. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010; 28: 2925-2935.
6. Berry SR, Neumann PJ, Bell C, et al. What price for a year of life? A survey of US and Canadian oncologists [abstract]. J Clin Oncol. 2009; 27: 339s. Abstract 6565.
7. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20: 2109-2117.
8. Vickers AJ,. Do we want more cancer patients on clinical trials if so, what are the barriers to greater accrual. Trials. 2008; 9: 31.
9. Cheng SK, Dietrich MS, Finnigan S, et al. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies [abstract]. J Clin Oncol. 2009; 27: 325s. Abstract CRA6509.
10. Dilts DM, Sandler AB, Cheng SK, et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol. 2009; 27: 1761-1766.
11. Schechter AN,. The crisis in clinical research: endangering the half-century National Institutes of Health Consensus. JAMA. 1998; 280: 1440-1442.
12. Bardach E, Kagan RA,. Going by the Book: The Problem of Regulatory Unreasonableness. 2nd ed. New Brunswick, NJ: Transaction Books; 2002.
13. Wikipedia. Contract Research Organizations. en.wikipedia.org/wiki/ Contract-research-organization#Market-size-and-growth. Accessed March 7, 2013.
14. Bauchner H, Fontanarosa P,. Restoring confidence in the pharmaceutical industry. JAMA. 2013; 309: 607-609.